A Mobile Phone-Based Program to Promote Healthy Behaviors Among Adults With Prediabetes Who Declined Participation in Free Diabetes Prevention Programs: Mixed-Methods Pilot Randomized Controlled Trial.


Journal

JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439

Informations de publication

Date de publication:
09 01 2019
Historique:
received: 09 06 2018
accepted: 10 09 2018
revised: 23 08 2018
entrez: 11 1 2019
pubmed: 11 1 2019
medline: 11 1 2019
Statut: epublish

Résumé

Despite evidence that Diabetes Prevention Programs (DPPs) can delay or prevent progression to type 2 diabetes mellitus (T2DM), few individuals with prediabetes enroll in offered programs. This may be in part because many individuals with prediabetes have low levels of autonomous motivation (ie, motivation that arises from internal sources) to prevent T2DM. This study aims to examine the feasibility and acceptability of a mobile health (mHealth) intervention designed to increase autonomous motivation and healthy behaviors among adults with prediabetes who previously declined participation free DPPs. In addition, the study aims to examine changes in autonomous motivation among adults offered 2 versions of the mHealth program compared with an information-only control group. In this 12-week, parallel, 3-arm, mixed-methods pilot randomized controlled trial, participants were randomized to (1) a group that received information about prediabetes and strategies to prevent T2DM (control); (2) a group that received a mHealth app that aims to increase autonomous motivation among users (app-only); or (3) a group that received the app plus a physical activity tracker and wireless-enabled digital scale for self-monitoring (app-plus). Primary outcome measures included rates of intervention uptake (number of individuals enrolled/number of individuals assessed for eligibility), retention (number of 12-week survey completers/number of participants), and adherence (number of device-usage days). The secondary outcome measure was change in autonomous motivation (measured using the Treatment Self-Regulation Questionnaire), which was examined using difference-in-difference analysis. Furthermore, we conducted postintervention qualitative interviews with participants. Overall, 28% (69/244) of eligible individuals were randomized; of these, 80% (55/69) completed the 12-week survey. Retention rates were significantly higher among app-plus participants than participants in the other 2 study arms combined (P=.004, χ Among individuals with prediabetes who did not engage in free DPPs, this mHealth intervention was feasible and acceptable. Future work should (1) examine the effectiveness of a refined intervention on clinically relevant outcomes (eg, weight loss) among a larger population of DPP nonenrollees with low baseline autonomous motivation and (2) identify other factors associated with DPP nonenrollment, which may serve as additional potential targets for interventions. ClinicalTrials.gov NCT03025607; https://clinicaltrials.gov/ct2/show/NCT03025607 (Archived by WebCite at http://www.webcitation.org/73cvaSAie).

Sections du résumé

BACKGROUND
Despite evidence that Diabetes Prevention Programs (DPPs) can delay or prevent progression to type 2 diabetes mellitus (T2DM), few individuals with prediabetes enroll in offered programs. This may be in part because many individuals with prediabetes have low levels of autonomous motivation (ie, motivation that arises from internal sources) to prevent T2DM.
OBJECTIVE
This study aims to examine the feasibility and acceptability of a mobile health (mHealth) intervention designed to increase autonomous motivation and healthy behaviors among adults with prediabetes who previously declined participation free DPPs. In addition, the study aims to examine changes in autonomous motivation among adults offered 2 versions of the mHealth program compared with an information-only control group.
METHODS
In this 12-week, parallel, 3-arm, mixed-methods pilot randomized controlled trial, participants were randomized to (1) a group that received information about prediabetes and strategies to prevent T2DM (control); (2) a group that received a mHealth app that aims to increase autonomous motivation among users (app-only); or (3) a group that received the app plus a physical activity tracker and wireless-enabled digital scale for self-monitoring (app-plus). Primary outcome measures included rates of intervention uptake (number of individuals enrolled/number of individuals assessed for eligibility), retention (number of 12-week survey completers/number of participants), and adherence (number of device-usage days). The secondary outcome measure was change in autonomous motivation (measured using the Treatment Self-Regulation Questionnaire), which was examined using difference-in-difference analysis. Furthermore, we conducted postintervention qualitative interviews with participants.
RESULTS
Overall, 28% (69/244) of eligible individuals were randomized; of these, 80% (55/69) completed the 12-week survey. Retention rates were significantly higher among app-plus participants than participants in the other 2 study arms combined (P=.004, χ
CONCLUSIONS
Among individuals with prediabetes who did not engage in free DPPs, this mHealth intervention was feasible and acceptable. Future work should (1) examine the effectiveness of a refined intervention on clinically relevant outcomes (eg, weight loss) among a larger population of DPP nonenrollees with low baseline autonomous motivation and (2) identify other factors associated with DPP nonenrollment, which may serve as additional potential targets for interventions.
TRIAL REGISTRATION
ClinicalTrials.gov NCT03025607; https://clinicaltrials.gov/ct2/show/NCT03025607 (Archived by WebCite at http://www.webcitation.org/73cvaSAie).

Identifiants

pubmed: 30626566
pii: v7i1e11267
doi: 10.2196/11267
pmc: PMC6329413
doi:

Banques de données

ClinicalTrials.gov
['NCT03025607']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

e11267

Subventions

Organisme : HSRD VA
ID : IK2 HX001517
Pays : United States
Organisme : NIDDK NIH HHS
ID : K01 DK107456
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020572
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK092926
Pays : United States

Informations de copyright

©Dina Griauzde, Jeffrey T. Kullgren, Brad Liestenfeltz, Tahoora Ansari, Emily H Johnson, Allison Fedewa, Laura R Saslow, Caroline Richardson, Michele Heisler. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 09.01.2019.

Références

Chronic Illn. 2010 Sep;6(3):202-14
pubmed: 20675362
Am J Prev Med. 2013 Nov;45(5):583-9
pubmed: 24139771
Int J Behav Nutr Phys Act. 2012 Mar 02;9:24
pubmed: 22385839
Psychol Health. 2010 Dec;25(10):1229-45
pubmed: 20204937
Prev Med. 2017 Jul;100:194-207
pubmed: 28456513
JMIR Mhealth Uhealth. 2018 Jan 17;6(1):e23
pubmed: 29343463
Arthritis Care Res (Hoboken). 2010 Mar;62(3):371-7
pubmed: 20391483
J Med Internet Res. 2018 Jun 19;20(6):e10528
pubmed: 29921561
BMJ Open Diabetes Res Care. 2016 Sep 15;4(1):e000212
pubmed: 27738513
JMIR Mhealth Uhealth. 2017 Jun 08;5(6):e80
pubmed: 28596147
J Med Internet Res. 2015 Apr 10;17(4):e92
pubmed: 25863515
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
J Health Soc Behav. 2013;54(3):353-68
pubmed: 23988727
J Med Internet Res. 2014 Aug 15;16(8):e192
pubmed: 25131661
Lancet Diabetes Endocrinol. 2015 Mar;3(3):173-80
pubmed: 25652129
JMIR Mhealth Uhealth. 2015 Nov 04;3(4):e101
pubmed: 26537656
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
Psychol Health Med. 2017 Mar;22(3):332-344
pubmed: 26952696
Int J Behav Nutr Phys Act. 2017 May 5;14(1):61
pubmed: 28476118
Int J Behav Nutr Phys Act. 2012 Mar 02;9:22
pubmed: 22385818
Med Sci Sports Exerc. 2011 Apr;43(4):728-37
pubmed: 20689448
Lancet Diabetes Endocrinol. 2015 Mar;3(3):160-1
pubmed: 25652128
J Pers Soc Psychol. 1996 Jan;70(1):115-26
pubmed: 8558405
Diabetes Care. 2013 Apr;36(4):1033-46
pubmed: 23468086
JMIR Mhealth Uhealth. 2015 Jun 15;3(2):e66
pubmed: 26076688
J Med Internet Res. 2016 Oct 31;18(11):e287
pubmed: 27806926
Diabetes Care. 2014 Apr;37(4):922-33
pubmed: 24652723
Curr Diab Rep. 2017 Sep 23;17(11):107
pubmed: 28942537
Health Educ Res. 2007 Oct;22(5):691-702
pubmed: 17138613
BMC Med. 2015 Apr 16;13:84
pubmed: 25907778

Auteurs

Dina Griauzde (D)

Veterans Affairs Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, MI, United States.
University of Michigan Medical School, Ann Arbor, MI, United States.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States.

Jeffrey T Kullgren (JT)

University of Michigan School of Dentistry, Ann Arbor, MI, United States.

Brad Liestenfeltz (B)

University of Michigan School of Nursing, Ann Arbor, MI, United States.

Tahoora Ansari (T)

University of Michigan School of Public Health, Ann Arbor, MI, United States.

Emily H Johnson (EH)

University of Michigan Medical School, Ann Arbor, MI, United States.

Allison Fedewa (A)

University of Michigan School of Dentistry, Ann Arbor, MI, United States.

Laura R Saslow (LR)

University of Michigan School of Nursing, Ann Arbor, MI, United States.

Caroline Richardson (C)

University of Michigan Medical School, Ann Arbor, MI, United States.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States.

Michele Heisler (M)

University of Michigan Medical School, Ann Arbor, MI, United States.
Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States.
University of Michigan School of Dentistry, Ann Arbor, MI, United States.
University of Michigan School of Public Health, Ann Arbor, MI, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH